The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.
|Autori interni:||ANTONIOLI, LUCA|
|Autori:||Antonioli, L; Pacher, P; Vizi, Es; Haskó, G|
|Titolo:||CD39 and CD73 in immunity and inflammation|
|Anno del prodotto:||2013|
|Digital Object Identifier (DOI):||10.1016/j.molmed.2013.03.005|
|Appare nelle tipologie:||1.1 Articolo in rivista|